News
On behalf of an individual investor, Block & Leviton LLP filed a class action lawsuit today against Hims & Hers Health, Inc. (NYSE: HIMS), along with certain individuals, alleging that they violated ...
Compounded weight loss drugs have been mostly off the market for about a month, but the weight loss drug industry remains as unsettled as ever.
The breakup between Novo Nordisk and Hims & Hers remains acrimonious. Recent remarks highlight the competition facing Novo ...
Synthetic food dyes are added to 1 in 5 packaged foods and drinks sold by top U.S. food manufacturers, a new study says.
Shell (NYSE:SHEL) has denied a report that it is in talks to acquire oil rival BP (NYSE:BP). “This is further market ...
People living with an autoimmune disease are nearly twice as likely to suffer from mood problems like depression, anxiety or ...
Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.
In this week’s edition of InnovationRx, we look at health insurers' vows to improve prior authorization, Bell Labs’ IP ...
Despite Novo Nordisk (NVO) recently ending a partnership with Hims & Hers Health (NYSE:HIMS) to distribute its weight-loss ...
NVO Investors Have Opportunity to Join Novo Nordisk A/S Fraud Investigation with the Schall Law Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Novo Nordisk A/S ("Novo Nordisk" or "the Company") (NYSE: NVO) ...
Hims & Hers lost a valuable collaboration with Novo Nordisk over compounded GLP-1s. Could it hurt the company's potential to ...
More than 50 insurers have pledged to streamline and simplify the prior authorization process through six new commitments.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results